Evogene Financial Statements From 2010 to 2026

EVGN Stock

USD 1.14 0.05 4.59%

Evogene's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Evogene's valuation are provided below:

Gross Profit

5.2 M

Profit Margin

(0.34)

Market Capitalization

9.6 M

Enterprise Value Revenue

1.2096

Revenue

8 M

We have found one hundred twenty available fundamental signals for Evogene, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to verify Evogene's prevailing fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. As of the 5th of February 2026, Market Cap is likely to drop to about 12.7 M. In addition to that, Enterprise Value is likely to drop to about 10 M

Evogene Total Revenue

6.02 Million

Check Evogene financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Evogene's main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.5 M, Interest Expense of 201.5 K or Selling General Administrative of 6 M, as well as many indicators such as Price To Sales Ratio of 1.16, Dividend Yield of 0.0 or Days Sales Outstanding of 54.52. Evogene financial statements analysis is a perfect complement when working with Evogene Valuation or Volatility modules.

Build AI portfolio with Evogene Stock

Check out the analysis of Evogene Correlation against competitors.

To learn how to invest in Evogene Stock, please use our How to Invest in Evogene guide.

Evogene Balance Sheet

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Total Assets

62.8 M

35.9 M

75 M

Slightly volatile

Common Stock Shares Outstanding

4.9 M

5.1 M

20.5 M

Slightly volatile

Other Current Liabilities

3.6 M

5.2 M

4.6 M

Slightly volatile

Total Current Liabilities

22.6 M

21.5 M

9.6 M

Slightly volatile

Other Liabilities

17.8 M

17 M

8.2 M

Slightly volatile

Accounts Payable

1.1 M

1.4 M

Slightly volatile

Cash

19 M

13.8 M

21.9 M

Very volatile

Other Assets

1.09

1.15

27.8 K

Pretty Stable

Short Term Investments

8.6 K

9 K

36.6 M

Slightly volatile

Other Current Assets

3.6 M

3.4 M

1.3 M

Slightly volatile

Total Liabilities

15.9 M

28.8 M

15.7 M

Slightly volatile

Intangible Assets

10.8 M

14 M

11.7 M

Slightly volatile

Common Stock

438.3 K

417.4 K

203.5 K

Slightly volatile

Property Plant Equipment

4.7 M

3.7 M

5.5 M

Slightly volatile

Property Plant And Equipment Net

4.4 M

3.8 M

5.5 M

Slightly volatile

Current Deferred Revenue

953.4 K

614.7 K

1.6 M

Slightly volatile

Non Current Assets Total

13.7 M

21 M

12.5 M

Slightly volatile

Non Currrent Assets Other

2.1 M

2 M

368.3 K

Slightly volatile

Cash And Short Term Investments

13.1 M

13.8 M

57.7 M

Slightly volatile

Net Receivables

1.2 M

1.3 M

1.5 M

Slightly volatile

Common Stock Total Equity

157.2 K

230 K

157.5 K

Slightly volatile

Liabilities And Stockholders Equity

64.1 M

35.9 M

74.8 M

Slightly volatile

Non Current Liabilities Total

7 M

7.3 M

6.5 M

Slightly volatile

Other Stockholder Equity

225.2 M

313.1 M

198.1 M

Slightly volatile

Property Plant And Equipment Gross

30.4 M

29 M

11.1 M

Slightly volatile

Total Current Assets

18.5 M

19.4 M

60.7 M

Slightly volatile

Short Term Debt

13.2 M

12.6 M

4 M

Slightly volatile

Net Tangible Assets

11.8 M

12.4 M

64.3 M

Slightly volatile

Deferred Long Term Liabilities

76.1 K

80.1 K

210 K

Slightly volatile

Short and Long Term Debt

12.5 M

11.9 M

7.4 M

Slightly volatile

Capital Surpluse

207.6 M

236.8 M

195.2 M

Slightly volatile

Non Current Liabilities Other

3.7 M

4.2 M

3.5 M

Slightly volatile

Net Invested Capital

7.6 M

8 M

49.4 M

Slightly volatile

Net Working Capital

2.5 M

2.6 M

46.9 M

Slightly volatile

Capital Stock

251.7 K

417.4 K

200.4 K

Slightly volatile

Short and Long Term Debt Total

8.1 M

14.8 M

5.5 M

Slightly volatile

Long Term Debt Total

1.7 M

1.9 M

2 M

Slightly volatile

Capital Lease Obligations

1.8 M

2.3 M

2.6 M

Slightly volatile

Long Term Debt

11.3 M

11.9 M

10.3 M

Slightly volatile

Evogene Income Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Depreciation And Amortization

2.5 M

2.9 M

2.3 M

Slightly volatile

Interest Expense

201.5 K

142.6 K

171.5 K

Slightly volatile

Selling General Administrative

6 M

11.6 M

5.8 M

Slightly volatile

Total Revenue

6 M

7.7 M

7.9 M

Slightly volatile

Other Operating Expenses

29.6 M

34.8 M

27 M

Slightly volatile

Research Development

15.8 M

16.4 M

14.1 M

Slightly volatile

Cost Of Revenue

5.1 M

4.6 M

6.3 M

Slightly volatile

Total Operating Expenses

22.6 M

28.9 M

20.5 M

Slightly volatile

Interest Income

1.1 M

861.3 K

1.3 M

Slightly volatile

Minority Interest

3.5 M

1.8 M

2.2 M

Slightly volatile

Tax Provision

9.8 K

10.3 K

29.2 K

Slightly volatile

Reconciled Depreciation

2.7 M

2.9 M

2.4 M

Slightly volatile

Selling And Marketing Expenses

884.4 K

945.3 K

650 K

Slightly volatile

Evogene Cash Flow Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Stock Based Compensation

1.9 M

1.6 M

2.3 M

Pretty Stable

Begin Period Cash Flow

25.7 M

23.9 M

22.8 M

Pretty Stable

Depreciation

2.5 M

2.9 M

2.3 M

Slightly volatile

Capital Expenditures

535.2 K

563.4 K

1.5 M

Slightly volatile

Total Cash From Financing Activities

4 M

4.2 M

13.9 M

Slightly volatile

End Period Cash Flow

19 M

13.8 M

21.9 M

Very volatile

Sale Purchase Of Stock

10.7 M

9 M

23.6 M

Slightly volatile

Issuance Of Capital Stock

105.2 K

110.7 K

9.2 M

Slightly volatile

Financial Ratios

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Price To Sales Ratio

1.16

1.23

259

Very volatile

Days Sales Outstanding

54.52

57.39

168

Pretty Stable

Book Value Per Share

3.04

2.94

2.7751

Slightly volatile

Stock Based Compensation To Revenue

0.18

0.19

0.8054

Pretty Stable

Capex To Depreciation

0.27

0.29

0.7876

Slightly volatile

EV To Sales

0.92

0.97

252

Very volatile

Payables Turnover

2.97

2.51

3.18

Slightly volatile

Sales General And Administrative To Revenue

1.74

1.06

2.2677

Slightly volatile

Research And Ddevelopement To Revenue

1.67

1.76

6.6151

Slightly volatile

Capex To Revenue

0.0629

0.0662

0.3164

Very volatile

Cash Per Share

3.0

3.03

2.8058

Slightly volatile

Days Payables Outstanding

250

150

269

Slightly volatile

Income Quality

1.05

1.25

1.1096

Slightly volatile

Intangibles To Total Assets

0.15

0.28

0.1829

Slightly volatile

Net Debt To EBITDA

0.17

0.18

4.6401

Slightly volatile

Current Ratio

1.26

1.33

8.6601

Slightly volatile

Tangible Book Value Per Share

0.5

0.52

2.2268

Slightly volatile

Receivables Turnover

4.85

6.58

5.2082

Slightly volatile

Capex Per Share

0.0772

0.12

0.0821

Slightly volatile

Revenue Per Share

1.77

1.69

0.6003

Pretty Stable

Interest Debt Per Share

2.11

2.01

0.4572

Slightly volatile

Debt To Assets

0.31

0.29

0.1086

Slightly volatile

Days Of Payables Outstanding

250

150

269

Slightly volatile

Long Term Debt To Capitalization

0.29

0.42

0.2995

Slightly volatile

Total Debt To Capitalization

1.07

1.01

0.2736

Slightly volatile

Quick Ratio

1.16

1.22

9.8798

Slightly volatile

Net Income Per E B T

1.09

1.05

1.0045

Pretty Stable

Cash Ratio

0.89

0.94

2.9426

Pretty Stable

Days Of Sales Outstanding

54.52

57.39

168

Pretty Stable

Fixed Asset Turnover

1.24

2.3

1.3441

Slightly volatile

Debt Ratio

0.31

0.29

0.1086

Slightly volatile

Price Sales Ratio

1.16

1.23

259

Very volatile

Asset Turnover

0.26

0.25

0.1278

Pretty Stable

Gross Profit Margin

0.65

0.62

0.4179

Slightly volatile

Evogene Valuation Data

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Market Cap

12.7 M

13.3 M

1.1 B

Slightly volatile

Enterprise Value

10 M

10.5 M

1.1 B

Slightly volatile

Evogene Fundamental Market Drivers

Evogene Upcoming Events

	14th of March 2024 Upcoming Quarterly Report	View
	16th of May 2024 Next Financial Report	View
	31st of December 2023 Next Fiscal Quarter End	View
	14th of March 2024 Next Fiscal Year End	View
	30th of September 2023 Last Quarter Report	View
	31st of December 2022 Last Financial Announcement	View

About Evogene Financial Statements

Evogene investors utilize fundamental indicators, such as revenue or net income, to predict how Evogene Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.

	Last Reported	Projected for Next Year
Current Deferred Revenue	614.7 K	953.4 K
Total Revenue	7.7 M	6 M
Cost Of Revenue	4.6 M	5.1 M
Stock Based Compensation To Revenue	0.19	0.18
Sales General And Administrative To Revenue	1.06	1.74
Research And Ddevelopement To Revenue	1.76	1.67
Capex To Revenue	0.07	0.06
Revenue Per Share	1.69	1.77
Ebit Per Revenue	(3.00)	(3.15)

Pair Trading with Evogene

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Evogene position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Evogene will appreciate offsetting losses from the drop in the long position's value.

Moving together with Evogene Stock

0.73

EDIT

Editas Medicine

Pair Corr

Moving against Evogene Stock

0.79	DSGN	Design Therapeutics	Pair Corr
0.64	IMMP	Immutep Ltd ADR	Pair Corr
0.55	ENGN	enGene Holdings Common	Pair Corr
0.55	KYTX	Kyverna Therapeutics	Pair Corr
0.36	63E	ONWARD MEDICAL BV	Pair Corr

The ability to find closely correlated positions to Evogene could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Evogene when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Evogene - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Evogene to buy it.

The correlation of Evogene is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Evogene moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Evogene moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Evogene can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Evogene offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Evogene's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Evogene Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Evogene Stock:

How To Invest In Evogene

Details

Is Evogene Stock a good investment?

Details

What is Evogene's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Evogene Correlation against competitors.

To learn how to invest in Evogene Stock, please use our How to Invest in Evogene guide.

You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.

Will Biotechnology sector continue expanding? Could Evogene diversify its offerings? Factors like these will boost the valuation of Evogene. Projected growth potential of Evogene fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Evogene data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.

Earnings Share

(1.10)

Revenue Per Share

1.084

Quarterly Revenue Growth

(0.83)

Return On Assets

(0.31)

Return On Equity

(0.71)

Investors evaluate Evogene using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Evogene's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Evogene's market price to deviate significantly from intrinsic value.

It's important to distinguish between Evogene's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Evogene should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Evogene's market price signifies the transaction level at which participants voluntarily complete trades.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Evogene Financial Statements From 2010 to 2026

Evogene Total Revenue

6.02 Million

Evogene Balance Sheet

Evogene Income Statement

Evogene Cash Flow Statement

Financial Ratios

Evogene Valuation Data

Evogene Fundamental Market Drivers

Evogene Upcoming Events

About Evogene Financial Statements

Pair Trading with Evogene

Moving together with Evogene Stock

Moving against Evogene Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY